Kakkis Emil D's Form 4 filing
Ultragenyx Pharmaceutical Inc. (RARE) · filed Mar 4, 2025
- Accession no.
- 0000950170-25-032779
- Filed
- Mar 4, 2025
- Trade date
- Feb 28-Mar 3, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $4.15M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kakkis Emil DCIK 0001248093 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2025 | Common Stock | AGrant or awardAcquired | +43,268 | $0.00 | $0 | 607,873 | Direct | |
| Mar 1, 2025 | Common Stock | AGrant or awardAcquired | +107,292 | $0.00 | $0 | 715,165 | Direct | |
| Mar 3, 2025 | Common Stock | SSaleDisposed | −73,434 | $42.10 | −$3,091,571.4 | 641,731 | Direct | |
| Feb 28, 2025 | Common Stock | SSaleDisposed | −25,000 | $42.48 | −$1,062,000 | 2,158,985 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2025 | Common Stock | AGrant or awardAcquired | +78,448 | $0.00 | $0 | 78,448 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.